September 23, 2019

FDA: Class I recall of Allergan Natrelle Biocell textured breast implants

By: Judy Mathias
Share

Editor's Note

The Food & Drug Administration (FDA) on September 12 designated the recall by Allergan of its Natrelle Biocell textured breast implants as Class I, the most serious.

The recall was initiated because of a six times higher rate of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), a cancer of the immune system, which has been associated with these implants.

Distribution dates are September 14, 2014, to July 24, 2019.

Read More >>

Get OR Manager Updates

Sign Up Now
Latest Issue of OR Manager
October 2022
Video Spotlight
Live chat by BoldChat